Literature DB >> 24234398

Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.

Archyut Valluri, Allan D Struthers, Chim C Lang.   

Abstract

Because of the impressive record of ACE inhibitors in patients with heart failure with reduced ejection fraction, the renin-angiotensin-aldosterone system continues to be pursued as a therapeutic target. Furthermore, the optimal treatment of patients with heart failure with preserved ejection fraction remains unclear. Early trials of direct renin inhibitors suggested that they may have a role, but recent results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look positive. Whether these or other drugs will alter current recommendations remains to be seen.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24234398     DOI： 10.1007/s11897-013-0173-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  65 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

Authors:  Joep H M van Esch; Els Moltzer; Richard van Veghel; Ingrid M Garrelds; Frank Leijten; Angelique M Bouhuizen; A H Jan Danser
Journal:  J Hypertens       Date:  2010-10       Impact factor: 4.844

3.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

4.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

5.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

7.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 9.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

Authors:  John J V McMurray; William T Abraham; Kenneth Dickstein; Lars Køber; Barry M Massie; Henry Krum
Journal:  Eur J Heart Fail       Date:  2012-04       Impact factor: 15.534

10.  (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function.

Authors:  Anne-Mari Moilanen; Jaana Rysä; Raisa Serpi; Erja Mustonen; Zoltán Szabò; Jani Aro; Juha Näpänkangas; Olli Tenhunen; Meeri Sutinen; Tuula Salo; Heikki Ruskoaho
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240
View more
  1 in total

Review 1.  Novel drug targets in clinical development for heart failure.

Authors:  Melvin George; Muthukumar Rajaram; Elangovan Shanmugam; Thangavel Mahalingam VijayaKumar
Journal:  Eur J Clin Pharmacol       Date:  2014-04-09       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.